Jun 15, 2026 06:41AM
Jun 15, 2026 06:40AM
Jun 11, 2026 08:00AM
May 30, 2026 02:30PM
May 27, 2026 07:02AM
May 27, 2026 07:00AM
May 13, 2026 04:05PM Precigen Reports First Quarter 2026 Financial Results and Business Updates
Apr 7, 2026 07:01AM
Apr 7, 2026 07:00AM
Mar 25, 2026 04:05PM
Jan 20, 2026 08:06AM
Jan 20, 2026 08:05AM
Jan 12, 2026 08:04AM
Jan 12, 2026 08:00AM Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Nov 13, 2025 04:05PM
Oct 13, 2025 07:01AM
Oct 13, 2025 07:00AM
Aug 25, 2025 08:05AM
Aug 19, 2025 06:38AM
Aug 15, 2025 07:00AM
Aug 15, 2025 07:00AM Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis
May 15, 2025 07:22AM
May 14, 2025 04:05PM
Apr 16, 2025 08:05AM
Mar 20, 2025 06:41AM
Mar 19, 2025 04:05PM
Feb 25, 2025 09:10AM
Feb 25, 2025 08:05AM Precigen Inc. (PGEN) Granted FDA Priority Review for PRGN-2012
Feb 25, 2025 08:05AM
Jan 13, 2025 07:00AM
Jan 2, 2025 04:00PM
Dec 30, 2024 07:00AM
Nov 14, 2024 04:30PM
Aug 14, 2024 04:05PM
Aug 6, 2024 04:08PM Precigen Inc. (PGEN) Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch
Aug 6, 2024 04:01PM
Jul 23, 2024 08:01AM
Jul 23, 2024 08:01AM
Jun 3, 2024 09:30AM
Jun 3, 2024 09:30AM
May 23, 2024 05:00PM
May 14, 2024 04:05PM Precigen Reports First Quarter 2024 Financial Results and Business Updates
Apr 24, 2024 10:20AM
Mar 28, 2024 04:05PM
Mar 20, 2024 03:16PM
Mar 19, 2024 04:05PM
Mar 12, 2024 04:05PM
Jan 16, 2024 08:05AM
Jan 16, 2024 08:05AM Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
Jan 8, 2024 08:37AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All